A new meta-analysis pooled data from studies across Africa to estimate how often people with Schistosoma parasites also carry Salmonella bacteria. This combined infection is described as an under-recognized public health concern. The overall pooled prevalence was 9%. When broken down by parasite type, Schistosoma mansoni with Salmonella was 4%, and Schistosoma haematobium with Salmonella was 12%. Country-level numbers varied widely. For S. mansoni with Salmonella, Ethiopia was 2%, Sudan 9%, the Democratic Republic of Congo 2%, and Nigeria 4%. For S. haematobium with Salmonella, Ethiopia was 0%, Sudan 25%, and Nigeria 8%. The analysis also looked at biological mechanisms and antimicrobial resistance, but the provided results do not include details on those. No safety information was reported. The review lists no limitations, no funding or conflict information, and no certainty assessment, so it is hard to judge how strong the underlying evidence is. Readers should treat these figures as a broad estimate of co-infection frequency in Africa, not as a personal risk number. Anyone concerned about these infections should talk with a doctor.
Schistosoma and Salmonella Co-infection Prevalence Across Various African RegionsParasite and Salmonella Co-Infections Found in 9% Across Africa
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis investigates the prevalence of concurrent Schistosoma and Salmonella infections among populations in Africa. The study identifies a pooled prevalence of 9% for co-infection, highlighting the significant overlap between these two parasitic and bacterial infections in the region.
Specific data indicates varying rates based on the species involved. Schistosoma mansoni and Salmonella co-infection was found at a 4% prevalence, while Schistosoma haematobium and Salmonella co-infection showed a higher prevalence of 12%. These findings suggest that Schistosoma haematobium may be more frequently associated with Salmonella infections.
Geographic analysis reveals significant regional variations. For Schistosoma haematobium, prevalence reached 25% in Sudan, compared to 8% in Nigeria and 0% in Ethiopia. For Schistosoma mansoni, prevalence was highest in Sudan at 9%, with lower rates observed in Ethiopia, the Democratic Republic of Congo, and Nigeria.
Clinicians should note that Schistosoma-Salmonella co-infection remains an under-recognized public health issue. The higher prevalence associated with Schistosoma haematobium suggests that regional and species-specific factors may influence the risk of co-infection, necessitating targeted screening and management strategies in endemic areas.
How this fits prior evidence
This meta-analysis extends prior coverage of neglected tropical disease burden and surveillance. It provides a pooled prevalence estimate for Schistosoma-Salmonella co-infection, a topic not addressed in earlier items. The finding that S. haematobium co-infection prevalence (12%) exceeds S. mansoni (4%) adds species-specific detail. It also aligns with prior coverage of Salmonella prevalence in bovine deep tissue lymph nodes (10.8% across 33 studies), reinforcing that Salmonella exposure is a measurable concern in African settings. The wide country-level variation (0% to 25%) echoes the caution urged for other pooled prevalence ranges, which should be treated as planning inputs rather than fixed estimates.
Common questions
How common is Schistosoma and Salmonella co-infection in Africa?
The pooled prevalence was 9% across the studies included. By parasite type, Schistosoma mansoni with Salmonella was 4%, and Schistosoma haematobium with Salmonella was 12%. These are combined estimates, and rates differed a lot from country to country.
Which countries had higher co-infection rates?
For Schistosoma haematobium with Salmonella, Sudan had 25%, Nigeria 8%, and Ethiopia 0%. For Schistosoma mansoni with Salmonella, Sudan had 9%, Nigeria 4%, Ethiopia 2%, and the Democratic Republic of Congo 2%. These numbers come from the studies pooled in this analysis.
Is this co-infection dangerous or does it cause side effects?
The provided results do not report safety information or adverse events. The analysis notes that co-infection is an under-recognized public health concern in Africa and looked at antimicrobial resistance, but no specific safety findings are included. Ask a doctor about any personal health concerns.
How strong is the evidence behind these numbers?
The review does not report limitations, funding, conflicts, or a certainty assessment, so it is hard to judge the strength of the underlying evidence. The figures are pooled estimates from multiple studies, not individual risk predictions. Treat them as a broad picture rather than a precise personal risk.
More on Salmonellosis
View Original Abstract ↓
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals
New data shows prevalence of fungal infections in HIV patients
Related in Infectious Disease
From Other Specialties
